Galixir Investor
Founded in 2019, Galixir is a company dedicated to applying cutting-edge artificial intelligence technologies to empower drug discovery. Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Galixir leverages cutting-edge AI algorithms to resolve problems in preclinical development of small molecule drugs and find candidate molecules with high potency, good druggability and novel structures.
Total Funding:
10000000.0
Headquarters:
Shenzhen, Guangdong, China
Funding Status:
Early Stage Venture
Employee Number:
28
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series A
Technology:
AI for Longevity
Investor Type:
For Profit
Last Funding Date:
2020-12-29
Investors Number:
4.0
Founded Date:
2019-01-01
Industry:
DeepTech